Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study

BACKGROUND: Ritonavir-boosted saquinavir (SQVr) is nowadays regarded as an alternative antiretroviral drug probably due to several drawbacks, such as its high pill burden, twice daily dosing and the requirement of 200 mg ritonavir when given at the current standard 1000/100 mg bid dosing. Several on...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Cortés, Luis F, Viciana, Pompeyo, Ruiz-Valderas, Rosa, Pasquau, Juan, Ruiz, Josefa, Lozano, Fernando, Merino, Dolores, Vergara, Antonio, Terrón, Alberto, González, Luis, Rivero, Antonio, Muñoz-Sanz, Agustin
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847537/
https://www.ncbi.nlm.nih.gov/pubmed/20236544
http://dx.doi.org/10.1186/1742-6405-7-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847537/
https://www.ncbi.nlm.nih.gov/pubmed/20236544
http://dx.doi.org/10.1186/1742-6405-7-5

Ejemplares similares